What does PD-L1 positive or negative mean?

被引：271

作者：

Ribas, Antoni ^{[1
,2
]}

Hu-Lieskovan, Siwen ^{[1
,2
]}

机构：

[1] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, JCCC, Los Angeles, CA 90095 USA

来源：

JOURNAL OF EXPERIMENTAL MEDICINE | 2016年 / 213卷 / 13期

基金：

美国国家卫生研究院;

关键词：

CELL LUNG-CANCER; ADAPTIVE IMMUNE RESISTANCE; ADVANCED MELANOMA; UNTREATED MELANOMA; CLINICAL ACTIVITY; HODGKIN LYMPHOMA; OPEN-LABEL; EXPRESSION; BLOCKADE; NIVOLUMAB;

D O I：

10.1084/jem.20161462

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.

引用

页码：2835 / 2840

页数：6

共 47 条

[1] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[2] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[3] PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].

Blank, C ;

Brown, I ;

Peterson, AC ;

Spiotto, M ;

Iwai, Y ;

Honjo, T ;

Gajewski, TF .

CANCER RESEARCH, 2004, 64 (03) :1140-1145

[4] MYC regulates the antitumor immune response through CD47 and PD-L1 [J].

Casey, Stephanie C. ;

Tong, Ling ;

Li, Yulin ;

Do, Rachel ;

Walz, Susanne ;

Fitzgerald, Kelly N. ;

Gouw, Arvin M. ;

Baylot, Virginie ;

Guetgemann, Ines ;

Eilers, Martin ;

Felsher, Dean W. .

SCIENCE, 2016, 352 (6282) :227-231

[5] Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients [J].

Cha, Edward ;

Klinger, Mark ;

Hou, Yafei ;

Cummings, Craig ;

Ribas, Antoni ;

Faham, Malek ;

Fong, Lawrence .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (238)

[6] Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity [J].

Dorand, R. Dixon ;

Nthale, Joseph ;

Myers, Jay T. ;

Barkauskas, Deborah S. ;

Avril, Stefanie ;

Chirieleison, Steven M. ;

Pareek, Tej K. ;

Abbott, Derek W. ;

Stearns, Duncan S. ;

Letterio, John J. ;

Huang, Alex Y. ;

Petrosiute, Agne .

SCIENCE, 2016, 353 (6297) :399-403

[7] IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression [J].

Dunn, GP ;

Sheehan, KCF ;

Old, LJ ;

Schreiber, RD .

CANCER RESEARCH, 2005, 65 (08) :3447-3453

[8] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].

Garon, Edward B. ;

Rizvi, Naiyer A. ;

Hui, Rina ;

Leighl, Natasha ;

Balmanoukian, Ani S. ;

Eder, Joseph Paul ;

Patnaik, Amita ;

Aggarwal, Charu ;

Gubens, Matthew ;

Horn, Leora ;

Carcereny, Enric ;

Ahn, Myung-Ju ;

Felip, Enriqueta ;

Lee, Jong-Seok ;

Hellmann, Matthew D. ;

Hamid, Omid ;

Goldman, Jonathan W. ;

Soria, Jean-Charles ;

Dolled-Filhart, Marisa ;

Rutledge, Ruth Z. ;

Zhang, Jin ;

Lunceford, Jared K. ;

Rangwala, Reshma ;

Lubiniecki, Gregory M. ;

Roach, Charlotte ;

Emancipator, Kenneth ;

Gandhi, Leena .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028

[9] Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma [J].

Green, Michael R. ;

Monti, Stefano ;

Rodig, Scott J. ;

Juszczynski, Przemyslaw ;

Currie, Treeve ;

O'Donnell, Evan ;

Chapuy, Bjoern ;

Takeyama, Kunihiko ;

Neuberg, Donna ;

Golub, Todd R. ;

Kutok, Jeffery L. ;

Shipp, Margaret A. .

BLOOD, 2010, 116 (17) :3268-3277

[10] Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J].

Herbst, Roy S. ;

Soria, Jean-Charles ;

Kowanetz, Marcin ;

Fine, Gregg D. ;

Hamid, Omid ;

Gordon, Michael S. ;

Sosman, Jeffery A. ;

McDermott, David F. ;

Powderly, John D. ;

Gettinger, Scott N. ;

Kohrt, Holbrook E. K. ;

Horn, Leora ;

Lawrence, Donald P. ;

Rost, Sandra ;

Leabman, Maya ;

Xiao, Yuanyuan ;

Mokatrin, Ahmad ;

Koeppen, Hartmut ;

Hegde, Priti S. ;

Mellman, Ira ;

Chen, Daniel S. ;

Hodi, F. Stephen .

NATURE, 2014, 515 (7528) :563-+

← 1 2 3 4 5 →